0001628280-26-031696
SEC filingZura Bio reported wider operating and net losses in Q1 FY2026 versus Q1 FY2025, driven by higher operating costs, consistent with its pre-commercial biotech profile and ongoing investment in tibulizumab development and public company infrastructure.
Diluted EPS for Q1 FY2026 was $-0.22, compared to $-0.19 in Q1 FY2025 — a 15.8% decline. This change reflects the proportional impact of the larger net loss on the weighted-average diluted share count, without introducing assumptions about share count dynamics beyond what is supported in the authoritative packet.
Management explicitly attributes the decline in interest income to two supported factors: lower prevailing interest rates and a lower cash balance for the majority of Q1 FY2026. The February 2026 Equity Offering proceeds were not received until the end of February, meaning the elevated cash balance did not meaningfully contribute to interest income during the quarter. This timing dynamic explains the reduced interest income without requiring unsupported quantification of the amount or its drivers.
Consistent with disclosures in Item 2, Zura Bio anticipates that both research and development expenses and general and administrative expenses will increase in the future. R&D growth is tied to ongoing clinical development of tibulizumab, while G&A growth reflects continued investment in public company infrastructure and support for expanding operations. These forward-looking statements are drawn directly from the business context packet and require no numeric supplementation to remain factual and investor-relevant.